- PRICING
- LIVE QUOTES
- LEARN
- HELP
More from Webull
Our Partners
EN
E
ERAS
Erasca, Inc.
11.24
-0.37-3.15%After Hours: 11.25 +0.01 +0.09%19:50 05/22 EDT
OPEN/PREV CLOSE11.63/11.61
TODAY RANGE11.18-11.72
VOL2.49M
MARKET CAP3.50B
52 WEEK RANGE1.060-24.28
AVG VOL (3M)6.65M
% TURNOVER0.80%
TURNOVER--
P/E (TTM)-12.0497
% RANGE4.65%
EPS(TTM)-0.9328
P/E(FORWARD)-11.7083
P/B8.88
BVPS1.266
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP2.85B
SHARES OUTSTANDING310.98M
NEXT EARNINGS08/10-08/14
FREE FLOAT253.16M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·1d ago
Erasca (ERAS) Is Up 9.9% After Merck Tie-Up And IP Challenge To ERAS-0015 - Has The Bull Case Changed?
Simply Wall St·3d ago
Erasca Merck Pact Puts ERAS 0015 KEYTRUDA Combo In Investor Focus
The Motley Fool·6d ago
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally
The Motley Fool·05/17 18:18
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
Seeking Alpha·05/17 11:29
Tango Therapeutics: 'Hold' On Combination Strategy Shift Of Vopimetostat
The Motley Fool·05/16 15:01
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
Simply Wall St·05/16 14:38
Assessing Erasca (ERAS) Valuation After ERAS-0015 Patent And Trade Secret Dispute
The Motley Fool·05/14 18:51
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700%
TipRanks·05/14 16:11
Adlai Nortye initiated with a Buy at JonesResearch
TipRanks·05/14 12:12
J.P. Morgan Keeps Their Buy Rating on Erasca (ERAS)
Simply Wall St·05/13 20:59
The Bull Case For Erasca (ERAS) Could Change Following New KEYTRUDA Alliance And ERAS-0015 Focus Shift
Seeking Alpha·05/12 15:01
Healthcare stocks with A+ momentum investors are watching
Dow Jones·05/12 13:11
Erasca Is Maintained at Outperform by Mizuho